Author

Alessandro Lovera

Observed names: A Lovera, Lovera, Alessandro

Institution: Angelini Pharma (Italy)

Observed institution: Angelini Pharma (Italy)

ORCID: 0009-0008-5802-6226

Observed ORCID: 0009-0008-5802-6226

OpenAlex ID: A5116757321

Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs ( EAP ) in Germany, France, and United Kingdom

2025 · Sylvain Rheims, Bernhard J. Steinhoff, et al. · Epilepsia Open · 17

195. Healthcare resource utilization among adult patients with focal-onset seizures using cenobamate: a US database analysis

2026 · A Lovera · The International Journal of Neuropsychopharmacology

Healthcare resource utilization in adults with focal onset seizures before and after initiating cenobamate: A US database analysis

2026 · Alessandro Lovera, Elena Alvarez-Baron, et al. · Epilepsy Research

AI-driven European Retrospective Database Study to predict disease onset in patients with epilepsy and depression

2026 · Alessandro Ruggieri, John Paul Leach, et al. · BMJ Neurology Open

Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis

2025 · Giancarlo Cerveri, Claudio Mencacci, et al. · International Journal of Psychiatry in Clinical Practice

Works count: 6

Citation count: 17

H-index: 1

I10-index: 1